Weld Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Weld Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-6,037	Closed	-$441K	–	728
2020 Q2	$441K	Buy	+6,037	New	+$321K	0.17%	209
2019 Q4	–	Sell	-11,009	Closed	-$459K	–	1086
2019 Q3	$459K	Buy	+11,009	New	+$465K	0.08%	407
2019 Q2	–	Sell	-4,803	Closed	-$247K	–	1056
2019 Q1	$247K	Buy	+4,803	New	+$207K	0.05%	551

Other funds holding BHVN

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Weld Capital Management's BHVN Position: Q3 2020 in Review

Weld Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2020, closing a stake of 6,037 shares — an estimated $441K sold.

Weld Capital Management first reported a position in BHVN in Q1 2019 and held it in 3 quarters. The position peaked at $459K in Q3 2019. 215 funds tracked by Wall St. Rank hold BHVN as of Q3 2020.

Weld Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2020 after selling out during the quarter.
Weld Capital Management sold 6,037 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2020, an estimated $441K.
Weld Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019 and held it in 3 quarters.
Weld Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $459K in Q3 2019.
215 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2020.

Based on Weld Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.